Finansiella nyckeltal HBM Healthcare Investments AG
Aktier
HBMN
CH0012627250
Investeringshantering & Fondsförvaltare
|
Marknaden stängd -
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
| 235,00 CHF | +0,86 % |
|
+0,21 % | +3,75 % |
| 07.45 | Värdet på HBM Healthcare Investments innehav rusar efter Parabilis Medicines börsnotering | MT |
| 06-01 | HBM Healthcare Investments slutför försäljningen av innehav i Swixx Biopharma | MT |
| Skatteperiod: Mars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Lönsamhet | ||||||||||
Return on Assets | −2,14 | −4,42 | 0,02 | 0,7 | 9,24 | |||||
Return on Total Capital | −2,15 | −4,43 | 0,02 | 0,7 | 9,26 | |||||
Return On Equity % | −3,77 | −7,78 | −0,06 | 1,11 | 15,58 | |||||
Return on Common Equity | −3,77 | −7,78 | −0,06 | 1,11 | 15,58 | |||||
Marginalanalys | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | −1,02 | −0,5 | 53,79 | 7,1 | 0,57 | |||||
EBITA Margin % | 102,08 | 101 | 17,44 | 88,79 | 99,07 | |||||
EBIT Margin % | 102,08 | 101 | 17,44 | 88,79 | 99,07 | |||||
Income From Continuing Operations Margin % | 105,76 | 102,86 | −36,32 | 83,07 | 98,59 | |||||
Net Income Margin % | 105,76 | 102,86 | −36,32 | 83,07 | 98,59 | |||||
Net Avail. For Common Margin % | 105,76 | 102,86 | −36,32 | 83,07 | 98,59 | |||||
Normalized Net Income Margin | 66,1 | 64,29 | −22,7 | 51,92 | 61,62 | |||||
Levered Free Cash Flow Margin | 77,73 | 64,2 | 12,12 | 51 | 61,57 | |||||
Unlevered Free Cash Flow Margin | 75,43 | 63,03 | 47,69 | 54,71 | 61,87 | |||||
Tillgångsomslutning | ||||||||||
Asset Turnover | −0,03 | −0,07 | 0 | 0,01 | 0,15 | |||||
Kortfristig likviditet | ||||||||||
Current Ratio | 2,64 | 0,11 | 3,1 | 0,81 | 1,83 | |||||
Quick Ratio | 2,64 | 0,11 | 3,1 | 0,81 | 1,83 | |||||
Operating Cash Flow to Current Liabilities | −4,99 | −0,02 | −0,51 | −0,76 | −0,91 | |||||
Långsiktig solvens | ||||||||||
Total Debt/Equity | 7,5 | 8,42 | 5,83 | 6,05 | 5,41 | |||||
Total Debt / Total Capital | 6,97 | 7,76 | 5,51 | 5,71 | 5,13 | |||||
LT Debt/Equity | 7,5 | 5,6 | 5,83 | 6,05 | 5,41 | |||||
Long-Term Debt / Total Capital | 6,97 | 5,16 | 5,51 | 5,71 | 5,13 | |||||
Total Liabilities / Total Assets | 7,06 | 7,87 | 5,68 | 5,87 | 5,28 | |||||
EBIT / Interest Expense | −27,72 | −54,24 | 0,31 | 14,95 | 206,17 | |||||
Tillväxt jämfört med föregående år | ||||||||||
Total Revenues, 1 Yr. Growth % | −109,6 | 92,79 | −102,1 | 648,56 | 1,14 tn | |||||
Gross Profit, 1 Yr. Growth % | −109,6 | 92,79 | −102,1 | 648,56 | 1,14 tn | |||||
EBITA, 1 Yr. Growth % | −109,93 | 90,76 | −100,36 | 3,71 tn | 1,28 tn | |||||
EBIT, 1 Yr. Growth % | −109,93 | 90,76 | −100,36 | 3,71 tn | 1,28 tn | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | −110,32 | 87,51 | −99,26 | −1,81 tn | 1,37 tn | |||||
Net Income, 1 Yr. Growth % | −110,32 | 87,51 | −99,26 | −1,81 tn | 1,37 tn | |||||
Normalized Net Income, 1 Yr. Growth % | −110,32 | 87,51 | −99,26 | −1,81 tn | 1,37 tn | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | −110,32 | 87,51 | −99,26 | −1,84 tn | 1,4 tn | |||||
Accounts Receivable, 1 Yr. Growth % | 17,65 | −20 | 275 | −38,33 | −54,05 | |||||
Total Assets, 1 Yr. Growth % | −5,5 | −9,98 | −6,11 | −3,24 | 11,37 | |||||
Tangible Book Value, 1 Yr. Growth % | −7,67 | −10,76 | −3,88 | −3,43 | 12,07 | |||||
Common Equity, 1 Yr. Growth % | −7,67 | −10,76 | −3,88 | −3,43 | 12,07 | |||||
Cash From Operations, 1 Yr. Growth % | 216,09 | −87,37 | 32,38 | 38,48 | 14,65 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | −111,96 | 59,22 | −100,4 | 3,05 tn | 1,39 tn | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | −111,57 | 61,1 | −101,59 | 758,78 | 1,3 tn | |||||
Dividend Per Share, 1 Yr. Growth % | 2,11 | −22,68 | 0 | 0 | 20 | |||||
Sammansatt Årlig Tillväxthastighet Över Två År | ||||||||||
Total Revenues, 2 Yr. CAGR % | −37,46 | −56,98 | −79,9 | −60,39 | 861,63 | |||||
Gross Profit, 2 Yr. CAGR % | −37,46 | −56,98 | −79,9 | −60,39 | 861,63 | |||||
EBITA, 2 Yr. CAGR % | −36,22 | −56,49 | −91,69 | −62,86 | 2,19 tn | |||||
EBIT, 2 Yr. CAGR % | −36,22 | −56,49 | −91,69 | −62,86 | 2,19 tn | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | −34,65 | −56,01 | −88,22 | −64,4 | 1,48 tn | |||||
Net Income, 2 Yr. CAGR % | −34,65 | −56,01 | −88,22 | −64,4 | 1,48 tn | |||||
Normalized Net Income, 2 Yr. CAGR % | −34,65 | −56,01 | −88,22 | −64,4 | 1,48 tn | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | −34,65 | −56,01 | −88,2 | −64,01 | 1,51 tn | |||||
Accounts Receivable, 2 Yr. CAGR % | −13,93 | −2,99 | 73,21 | 52,07 | −46,77 | |||||
Total Assets, 2 Yr. CAGR % | 17,35 | −7,77 | −8,07 | −4,68 | 3,81 | |||||
Tangible Book Value, 2 Yr. CAGR % | 17,1 | −9,23 | −7,39 | −3,66 | 4,03 | |||||
Common Equity, 2 Yr. CAGR % | 17,1 | −9,23 | −7,39 | −3,66 | 4,03 | |||||
Cash From Operations, 2 Yr. CAGR % | 56,6 | −36,81 | −59,11 | 35,39 | 26 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | −28,92 | −56,36 | −92,06 | −64,69 | 2,07 tn | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | −30,45 | −56,83 | −84,02 | −63,09 | 995,38 | |||||
Dividend Per Share, 2 Yr. CAGR % | 12,24 | −11,15 | −12,07 | 0 | 9,54 | |||||
Treårig Sammansatt Årlig Tillväxthastighet | ||||||||||
Total Revenues, 3 Yr. CAGR % | −30,04 | −8,98 | −84,29 | −32,87 | 24,69 | |||||
Gross Profit, 3 Yr. CAGR % | −30,04 | −8,98 | −84,29 | −32,87 | 24,69 | |||||
EBITA, 3 Yr. CAGR % | −29,12 | −8,1 | −91,18 | −35,92 | 23,89 | |||||
EBIT, 3 Yr. CAGR % | −29,12 | −8,1 | −91,18 | −35,92 | 23,89 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | −28 | −7,13 | −88,73 | −38,06 | 22,94 | |||||
Net Income, 3 Yr. CAGR % | −28 | −7,13 | −88,73 | −38,06 | 22,94 | |||||
Normalized Net Income, 3 Yr. CAGR % | −28 | −7,13 | −88,73 | −38,06 | 22,94 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | −28 | −7,13 | −88,72 | −37,6 | 24,66 | |||||
Accounts Receivable, 3 Yr. CAGR % | −8,37 | −16,01 | 52,25 | 22,76 | 2,04 | |||||
Total Assets, 3 Yr. CAGR % | 14,55 | 7,42 | −7,22 | −6,48 | 0,39 | |||||
Tangible Book Value, 3 Yr. CAGR % | 14,65 | 6,96 | −7,48 | −6,09 | 1,32 | |||||
Common Equity, 3 Yr. CAGR % | 14,65 | 6,96 | −7,48 | −6,09 | 1,32 | |||||
Cash From Operations, 3 Yr. CAGR % | 52,91 | −32,34 | −19,15 | −38,59 | 28,09 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | −24,22 | −7 | −90,9 | −41,67 | 22,97 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | −25,27 | −7,97 | −85,65 | −39,68 | 23,92 | |||||
Dividend Per Share, 3 Yr. CAGR % | 8,95 | −0,87 | −7,58 | −8,22 | 6,27 | |||||
Sammansatt Årlig Tillväxthastighet Över Fem År | ||||||||||
Total Revenues, 5 Yr. CAGR % | −12,32 | 3,27 | −57,52 | −34,74 | −18,54 | |||||
Gross Profit, 5 Yr. CAGR % | −12,32 | 3,27 | −57,52 | −34,74 | −18,54 | |||||
EBITA, 5 Yr. CAGR % | −11,56 | 3,96 | −69,93 | −36,04 | −18,48 | |||||
EBIT, 5 Yr. CAGR % | −11,56 | 3,96 | −69,93 | −36,04 | −18,48 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | −10,62 | 4,78 | −65,1 | −36,72 | −18,5 | |||||
Net Income, 5 Yr. CAGR % | −10,62 | 4,78 | −65,1 | −36,72 | −18,5 | |||||
Normalized Net Income, 5 Yr. CAGR % | −10,62 | 4,78 | −65,1 | −36,72 | −18,5 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | −9,97 | 4,91 | −65,07 | −36,44 | −17,82 | |||||
Accounts Receivable, 5 Yr. CAGR % | −17,07 | −15,44 | 18,2 | 6,5 | 0 | |||||
Total Assets, 5 Yr. CAGR % | 12,26 | 8,83 | 4,9 | 2,41 | −2,96 | |||||
Tangible Book Value, 5 Yr. CAGR % | 12,64 | 8,89 | 5,27 | 2,58 | −3,04 | |||||
Common Equity, 5 Yr. CAGR % | 12,64 | 8,89 | 5,27 | 2,58 | −3,04 | |||||
Cash From Operations, 5 Yr. CAGR % | 42,85 | −16,37 | −9,78 | −10,7 | −3,45 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | −7,85 | 4,98 | −69,27 | −36,87 | −18,75 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | −8,72 | 4,16 | −59,67 | −36,15 | −18,72 | |||||
Dividend Per Share, 5 Yr. CAGR % | 10,83 | 1,39 | 0 | −0,52 | −1,08 |
- Börsen
- Aktier
- HBMN Aktie
- Finanser HBM Healthcare Investments AG
- Finansiella nyckeltal
Välj din utgåva
All finansiell information anpassad till den nationella nivån
















